Gene Editing: Latest Developments

On Demand Webinar

Gene Editing: Latest Developments

Inside the world of gene editing – a closer look.

View our webinar for news and views on the latest developments.

Our expert panel, chaired by Madeleine Armstrong, News Editor at Evaluate Vantage and author of our latest report on gene editing, featured Sekar Kathiresan, co-founder and CEO of Verve Therapeutics, Amanda Miklus, Managing Consultant and Shardha Millington, Consultant at Citeline.

Watch now

I would like to receive Evaluate industry & market reports, and the latest news from Evaluate. エバリュエートの業界・市場レポートやイベント等最新ニュースを受け取る（無料）

Connect with our advisory team
Get insights on BD&L, portfolio, and competitive intelligence 業界特化型コンサルタントとの個別相談を希望する
BD&L／ポートフォリオ／競合インテリジェンスについて、担当者よりご連絡いたします

Your information will be used in accordance with our Privacy notice. ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。

About this webinar

After Crispr made a splash as a potential therapeutic approach a decade ago, the question remains: will gene editing ever become mainstream? Although the first product using Crispr/Cas9 gene editing is on the verge of approval, doubts persist.

The panel discussed topics such as:

The latest gene editing technology and trends in the market
The regulators’ stance on gene editing
The latest deal making activity and the reality of investment in gene editing companies

Core Forecasting Products

Regional Forecasts

Forecast Enablement

Bespoke Forecasting

Portfolio & Scenario Analysis

Competitive Context

Pipeline & Asset Intelligence

Deal and Asset Evaluation

Bespoke Business Development Analysis

Scientific & Pipeline Intelligence

Competitive Intelligence Platforms

Epidemiology Context

Market and Company Benchmarks

Custom Solutions

Support

Training and Enablement

Need Help?

Forecasting

Business Development & Licensing

Portfolio Strategy

Competitive Intelligence

Discover Resources

On Demand Webinar